121 related articles for article (PubMed ID: 26641559)
1. Layer by layer assembly of albumin nanoparticles with selective recognition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Cui W; Wang A; Zhao J; Yang X; Cai P; Li J
J Colloid Interface Sci; 2016 Mar; 465():11-7. PubMed ID: 26641559
[TBL] [Abstract][Full Text] [Related]
2. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
3. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/ALG modified CaCO
Cui W; Cui Y; Zhao J; Li J
J Mater Chem B; 2013 Mar; 1(9):1326-1332. PubMed ID: 32260806
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors.
Tummala S; Gowthamarajan K; Satish Kumar MN; Wadhwani A
Drug Deliv; 2016 Jun; 23(5):1773-87. PubMed ID: 26377238
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles.
Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J
Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790
[TBL] [Abstract][Full Text] [Related]
10. Dual-peptide-functionalized albumin-based nanoparticles with ph-dependent self-assembly behavior for drug delivery.
Chen B; He XY; Yi XQ; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15148-53. PubMed ID: 26168166
[TBL] [Abstract][Full Text] [Related]
11. Enzyme and Thermal Dual Responsive Amphiphilic Polymer Core-Shell Nanoparticle for Doxorubicin Delivery to Cancer Cells.
Kashyap S; Singh N; Surnar B; Jayakannan M
Biomacromolecules; 2016 Jan; 17(1):384-98. PubMed ID: 26652038
[TBL] [Abstract][Full Text] [Related]
12. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
[TBL] [Abstract][Full Text] [Related]
13. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
[TBL] [Abstract][Full Text] [Related]
14. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis.
Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A
Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
[TBL] [Abstract][Full Text] [Related]
16. Manipulating multifaceted microbubble shell composition to target both TRAIL-sensitive and resistant cells.
Jablonowski LJ; Conover D; Teraphongphom NT; Wheatley MA
J Biomed Mater Res A; 2018 Jul; 106(7):1903-1915. PubMed ID: 29521001
[TBL] [Abstract][Full Text] [Related]
17. Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo.
Riehle RD; Cornea S; Degterev A; Torchilin V
Drug Deliv; 2013 Feb; 20(2):78-85. PubMed ID: 23495715
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
19. [Synergistic effect of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and doxorubicin on human colon cancer SW480 cells].
Xu LH; Deng CS; Zhu YQ; Liu SQ
Ai Zheng; 2003 Aug; 22(8):816-20. PubMed ID: 12917026
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Erviti-Ardanaz S; Pazo-Cid R; del Agua C; Fernández LJ; Ochoa I; Anel A; Martinez-Lostao L
Nanotechnology; 2016 May; 27(18):185101. PubMed ID: 27001952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
